Finding 375625 (2022-008)

Material Weakness
Requirement
B
Questioned Costs
$1
Year
2022
Accepted
2024-03-12

AI Summary

  • Core Issue: The organization lacks proper controls to ensure that only allowable and reasonable costs are charged to federal awards, leading to questioned costs of approximately $12,100.
  • Impacted Requirements: Compliance with federal guidelines on allowable costs and internal controls over financial reporting is not being met, resulting in inaccurate expenditure reporting.
  • Recommended Follow-Up: Implement comprehensive controls for reviewing and approving costs, including independent reviews and proper documentation to ensure compliance with grant requirements.

Finding Text

#2022-008 - Major Federal Award Finding - Allowable Costs - Non-Payroll Nature of Finding: Compliance Finding - Allowable Costs and Material Weakness in Internal Controls Over Compliance Criteria/Condition: A non-federal entity may only charge allowable costs incurred by the entity that are necessary and reasonable for the administration of the program and are of a nature in line with the categories allowed in the grant budget. The Organization did not have controls in place to verify that costs were being charged to the award in the correct amount or for necessary and reasonable expenditures. Questioned Costs: Approximately $12,100 Identification of How Questioned Costs Were Computed: A sample of 40 non-payroll expenditures totaling approximately $92,000 was selected form a population of approximately $488,000 of non-payroll expenditures. Of the invoices selected for testing of non-payroll expenditures charged to the major program, $23 was charged to the grant in excess of invoiced amounts or for costs that were not necessary and reasonable. Questioned costs are estimated by projecting this error identified in the sample tested to the population of non-payroll expenditures of the Opioid STR program. Additionally, a questioned cost was identified for costs relating to the lease of a second space. Costs totaling up to $12,000 were allocated in part to the major program as office lease expenditures but were instead described to be an employee fringe benefit. These costs were determined to be outside of those necessary and reasonable for the administration of the program. Cause/Context: There are not proper controls in place to review invoices and ensure grant billings are in line with allowable costs incurred. Further, a portion of lease costs appear to be classified inconsistent with the underlying nature of the space. Effect: An overstatement of expenditures for the grant was reported and submitted for reimbursement. Recommendation: We recommend that a full-range of controls over costs charged to federal programs be implemented. The Organization should devote the resources necessary to ensure that such costs are of direct benefit to the program, are reviewed, approved, documented, and that the accounting and reporting process is accurate. Further, controls over grant billings should be established to ensure expenditures represent actual costs incurred. All control activities, including independent review should be documented and evidence of review and approval be maintained. Views of Responsible Officials and Planned Corrective Actions: MARR will retain a CPA consultant to implement a full range of controls over costs charged to federal programs. MARR's protocol shall ensure that such costs are the direct benefit to the program, are reviewed, approved, documented and ensure the accounting and reporting process be accurate. Further, controls over grant billings will be established to ensure expenditures represent actual costs incurred. All control activities, including independent review, should be documented and evidence of review and approval will be maintained.

Categories

Questioned Costs Allowable Costs / Cost Principles Cash Management Material Weakness Reporting Matching / Level of Effort / Earmarking Internal Control / Segregation of Duties

Other Findings in this Audit

  • 375613 2022-004
    Material Weakness
  • 375614 2022-005
    Material Weakness
  • 375615 2022-006
    Material Weakness
  • 375616 2022-007
    Material Weakness
  • 375617 2022-008
    Material Weakness
  • 375618 2022-009
    Material Weakness
  • 375619 2022-010
    Material Weakness
  • 375620 2022-011
    Material Weakness
  • 375621 2022-004
    Material Weakness
  • 375622 2022-005
    Material Weakness
  • 375623 2022-006
    Material Weakness
  • 375624 2022-007
    Material Weakness
  • 375626 2022-009
    Material Weakness
  • 375627 2022-010
    Material Weakness
  • 375628 2022-011
    Material Weakness
  • 952055 2022-004
    Material Weakness
  • 952056 2022-005
    Material Weakness
  • 952057 2022-006
    Material Weakness
  • 952058 2022-007
    Material Weakness
  • 952059 2022-008
    Material Weakness
  • 952060 2022-009
    Material Weakness
  • 952061 2022-010
    Material Weakness
  • 952062 2022-011
    Material Weakness
  • 952063 2022-004
    Material Weakness
  • 952064 2022-005
    Material Weakness
  • 952065 2022-006
    Material Weakness
  • 952066 2022-007
    Material Weakness
  • 952067 2022-008
    Material Weakness
  • 952068 2022-009
    Material Weakness
  • 952069 2022-010
    Material Weakness
  • 952070 2022-011
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $133,750
93.959 Block Grants for Prevention and Treatment of Substance Abuse $60,744